Singapore Clinical Trial: A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation.

Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation.'. The following are the other relevant details related to the trial:

Therapeutic Area: Oncology (including Haematology-Oncology)

Trial Centre(s): KK Women's & Children's Hospital

Trial Status: NA

Principal Investigator(s): Dr Prasad Ramanakrishnan Iyer

Published by HT Digital Content Services with permission from Health Daily Digest....